St. Vincent's Prostate Cancer Research Centre, Darlinghurst, NSW, Australia.
Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
BMC Urol. 2022 Mar 2;22(1):28. doi: 10.1186/s12894-022-00978-w.
To report the feasibility, oncological and functional outcomes of salvage robot-assisted radical prostatectomy (sRARP) for recurrent prostate cancer (PCa) after irreversible electroporation (IRE).
This was a retrospective analysis of patients who underwent sRARP by a single high-volume surgeon after IRE treatment in our institution. Surgical complications, oncological and functional outcomes were assessed.
15 patients with at least 12 months follow up were identified out of the 234 men who underwent primary IRE between 2013 and 2019. The median [IQR] age was 68 (62-70) years. The median [IQR] time from focal IRE to sRARP was 42 (21-57) months. There were no rectal, bladder or ureteric injuries. The T-stage was pT2 in 9 (60%) patients and pT3a in 6 (40%) patients. Only one (7%) patient had a positive surgical margin. At a median [IQR] follow up of 22 (16-32) months no patient had a biochemical recurrence (PSA > 0.2). All 15 patients were continent (pad-free) by 6 months and 9 (60%) patients had erections sufficient for intercourse with or without PDE5 inhibitors. No predisposing factors were identified for predicting erectile dysfunction after sRARP.
In patients with recurrent or residual significant PCa after focal IRE ablation it is feasible to obtain good functional and oncological outcomes with sRARP. Our results demonstrate that good outcomes can be achieved with sRARP, when respecting close monitoring post-IRE, good patient selection and surgical experience. The limitations of this study are that it is a small series, with short follow up and a lack of standardised quality of life instruments.
报告不可逆电穿孔(IRE)治疗后复发前列腺癌(PCa)患者行挽救性机器人辅助根治性前列腺切除术(sRARP)的可行性、肿瘤学和功能结果。
本研究回顾性分析了本中心 234 例行原发性 IRE 的患者,其中 15 例患者在 IRE 治疗后至少随访 12 个月行 sRARP。评估了手术并发症、肿瘤学和功能结果。
2013 年至 2019 年期间,共 234 例男性患者接受了原发性 IRE,其中 15 例患者至少随访 12 个月。患者年龄中位数(IQR)为 68(62-70)岁。IRE 至 sRARP 的中位(IQR)时间为 42(21-57)个月。无直肠、膀胱或输尿管损伤。T 分期 pT2 9 例(60%),pT3a 6 例(40%)。仅 1 例(7%)患者切缘阳性。中位(IQR)随访 22(16-32)个月,无生化复发(PSA>0.2)。15 例患者在 6 个月时均达到控尿(无尿垫),9 例(60%)患者无需 PDE5 抑制剂即可进行性交。未发现 sRARP 后发生勃起功能障碍的预测因素。
在接受局灶性 IRE 消融治疗后复发或残留有显著 PCa 的患者中,行 sRARP 可获得良好的功能和肿瘤学结果。我们的结果表明,在密切监测 IRE 后、良好的患者选择和手术经验的前提下,sRARP 可以获得良好的结果。本研究的局限性在于这是一个小系列研究,随访时间短,缺乏标准化的生活质量工具。